GENESIS-PHARMA
1.3.2024 09:38:30 CET | Business Wire | Press release
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy or in combination with chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and as monotherapy treatment for certain patients with recurrent or metastatic cervical cancer.
The two companies will work to seamlessly complete the transition of all relevant commercialization activities by the second quarter of 2024.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “For more than 20 years our company has been committed to ensure patient access to innovative therapies for serious diseases in several European markets building upon a constantly growing network of partners that includes leading global biopharma companies. It is thus our honor to initiate a new agreement with Regeneron, a pioneering company committed to cutting-edge science, that further enhances our long-term expertise and focus on medicines targeting difficult-to-treat cancers.”
About GENESIS Pharma: GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies.
For more information, please visit www.genesispharmagroup.com or follow GENESIS Pharma on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301136761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Expands Collaboration with Google Cloud to Help Accelerate Gemini Enterprise Adoption at Scale7.10.2026 10:30:00 CEST | Press release
Collaboration brings together a dedicated Gemini Enterprise CoE and Customer Experience Center LTM, a Business Creativity partner to the world’s largest enterprises, today announced an expanded collaboration with Google Cloud to help accelerate adoption of Google Cloud’s Gemini Enterprise. The collaboration will help organizations build, deploy, and scale AI-powered solutions by combining Gemini Enterprise capabilities with LTM's deep industry expertise, engineering talent, and global delivery capabilities. As part of this collaboration, LTM is making significant investments to strengthen its Gemini Enterprise capabilities through a dedicated Gemini Enterprise Center of Excellence (CoE), Specialized Talent and Delivery Capabilities and the development of Industry-Focused AI Solutions that will be showcased at the upcoming, state-of-the-art Gemini EnterpriseCustomer Experience Center. These efforts are designed to help organizations drive enterprise-wide AI adoption, operationalize inte
Gemcorp and Fonds Souverain Malagasy Announce Strategic Partnership to Support Investment in Madagascar7.10.2026 10:00:00 CEST | Press release
Gemcorp and the Fonds Souverain Malagasy (“FSM”) signed a strategic partnership during the 81st United Nations General Assembly (“UNGA”) in New York, establishing a framework to support investment and the development of Madagascar’s strategic assets. Under the leadership of His Excellency Michael Randrianirina, President of the Republic of Madagascar and guided by his vision to “transform the potential and endowments of the country into tangible impacts for the people,” the partnership will support FSM and the Government of Madagascar in advancing the country’s growth and investment agenda. This includes a particular focus on unlocking the value of Madagascar’s mineral resources, alongside its broader assets across mining, energy and infrastructure. As part of this partnership, FSM and the Government of Madagascar will set the strategic direction and priorities, with Gemcorp supporting FSM in structuring projects, developing investment and financing solutions, and connecting projects w
High Awareness, Low Adoption: New Survey Reveals Nearly Half of Security Professionals Still Rely on Passwords7.10.2026 09:01:00 CEST | Press release
Global study from Yubico and Okta highlights a critical execution gap in enterprise security, shows how modern identity controls can eliminate password dependency. A new survey from Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the original passkey, the YubiKey, and Okta, Inc., reveals a significant gap between security knowledge and everyday practice. While security leaders overwhelmingly recognize phishing-resistant passkeys as more secure than passwords, nearly half still rely on vulnerable login methods in their daily work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007969823/en/ Conducted by Talker Research, the annual 2026 Global State of Authentication* report surveyed nearly 2,000 cybersecurity and IT professionals across nine countries. The report highlights that cybersecurity's primary vulnerability is no longer a lack of education or awareness, but a stru
Wolters Kluwer brings AI-powered drafting directly into the Libra legal workspace7.10.2026 09:01:00 CEST | Press release
In addition to Libra’s existing Word Add-in, Drafting in Libra gives customers the flexibility to choose the drafting environment that best suits their workflow, while automatically applying their firm’s existing templates Wolters Kluwer Legal & Regulatory today announced the launch of Drafting, a major new capability within Libra by Wolters Kluwer, the company’s legal AI workspace. Drafting enables legal professionals to create, edit, review, and collaborate on Word documents directly within the workspace, reducing the need to switch between separate applications throughout the drafting process. Together with Libra's existing Word Add-in, which is already widely used by legal professionals today, the new capability provides customers with a second, fully integrated way to draft their documents. Depending on their preferences and workflow, they can either remain within the Microsoft Word environment or work end-to-end in the Libra legal AI workspace. At the core of Drafting is the Libr
ClaroNav Kolahi Inc. Announces EU MDR Certification for Navient Surgical Navigation System7.10.2026 09:00:00 CEST | Press release
ClaroNav Kolahi Inc. (CKI), a global developer and manufacturer of surgical navigation technologies, today announced that its Navient Surgical Navigation System has received certification under the European Union Medical Device Regulation, EU MDR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007890668/en/ ClaroNav Kolahi Inc. Announces EU MDR Certification for Navient Surgical Navigation System The certification covers the Navient Image Guided Navigation System and its reusable surgical instruments, allowing CKI to continue offering Navient throughout the European Union under the EU MDR regulatory framework. “EU MDR certification is an important milestone for CKI and demonstrates our continued commitment to meeting the highest standards for safety, quality, and regulatory compliance,” said Ahmad Kolahi, CEO of CKI. Navient was previously certified under EU MDD and has received regulatory approvals including US FDA, Heal
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom